Online inquiry

IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4457MR)

This product GTTS-WQ4457MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SLAMF7 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001282588.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57823
UniProt ID Q9NQ25
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4457MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1410MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACA125
GTTS-WQ9087MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMCgp100
GTTS-WQ13499MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRX002
GTTS-WQ5022MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA c4G7-N
GTTS-WQ12676MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ7823MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ474MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ9386MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Interleukin 2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW